We have been writing about the drug pipeline potential plus the very large 20 % short position.
The two came together today with the release of encouraging test results.
OPKO Announces Successful Confirmation of 4Kscore™ Algorithm in the United States
MIAMI–(BUSINESS WIRE)–Feb. 13, 2014– OPKO Health, Inc. (NYSE:OPK) announced the successful completion of the calibration confirmation phase of the 4Kscore™ test clinical validation study currently underway at 21 urology clinics in the United States.
The OPKO 4Kscore™ test clinical validation protocol involves two parts: a calibration confirmation phase and a validation phase. The calibration confirmation phase evaluated the applicability of the 4Kscore™ algorithm, developed using banked samples from European studies, to the OPKO study samples collected in the United States and shipped directly to OPKO Lab in Nashville, TN for testing. The results confirmed the validity of the algorithm. The study is now more than 50% complete toward the final goal of 1,200 subjects. These results support the U.S. launch of the 4Kscore™ test in March 2014.
“We are extremely pleased that results of the calibration phase confirmed the 4Kscore™ algorithm is an accurate predictor of prostate cancer, and especially aggressive disease,” said David Okrongly, President of OPKO Diagnostics. “The reproducibility of the algorithm speaks to the robustness of the biomarkers used in the 4Kscore™ algorithm, as well as the quality of the multiple clinical studies published in peer-reviewed journals.”
“These results reinforce our belief that the 4Kscore™ test will be an important addition to the urologists’ means of assessing a patient’s risk for aggressive prostate cancer as well as an important new diagnostic product for OPKO,” said Phillip Frost, M.D., OPKO’s Chairman and Chief Executive Officer.
About the 4Kscore™ Test
The 4Kscore™ is a convenient blood test that measures the serum levels of four different prostate-derived kallikrein proteins: total PSA, free PSA, intact PSA and hK2. Levels of these biomarkers are combined with a patient’s age and digital rectal exam (DRE) status using a proprietary algorithm to calculate the probability of a finding of aggressive prostate cancer. The 4Kscore™ test is based on over a decade of research of the four kallikrein panel of biomarkers conducted by scientists at Memorial Sloan Kettering Cancer Center and leading research centers in Europe on over 10,000 patients. The information provided by the 4Kscore™ test can help facilitate the shared decision-making process between urologist and patient in determining the advisability of a prostate biopsy
|Open||7.70||P/E Ratio (TTM)||—|
|Last Bid/Size||8.22 / 27||EPS (TTM)||-0.29|
|Last Ask/Size||8.23 / 68||Next Earnings||17 Mar 2014|
|Average Volume||2,761,322||Dividend Yield||0.00%|
|Day High||8.25||Ex-Dividend Date||—|
|Day Low||7.67||Shares Outstanding||408.0M|
|52 Week High||12.95||# of Floating Shares||217.3466M|
|52 Week Low||6.14||Short Interest as % of Float||21.13%|
1) Promissory notes – a rate equal to Second Mortgages – currently 12 % and the risk is the quality of the guarantee.
Paid monthly at the rate of 1 % you can earn a compound rate and lessen the total exposure.
Renewed every 12 months so you can withdraw all or a portion of funds.
2) Stock market Managed Accounts – unlimited potential but a risk that there is a market down turn of 30 or greater per cent.
You can elect to receive 1 % or more as a MONTH as a withdrawal to lessen your exposure.
Managed Accounts require a six month notice to withdraw but that is a formal requirement only to prevent a
” run” if there is a sharp turn in the market.
For assistance at obtaining the rates set out -please email email@example.com or call Jack direct at 604-858-3202 ( same time zone as Los Angeles)